Article
Oncology
Ashly Hindle, Balakrishna Koneru, Monish Ram Makena, Lluis Lopez-Barcons, Wan Hsi Chen, Thinh H. Nguyen, C. Patrick Reynolds
Summary: High MGMT expression is associated with resistance to alkylating agents and TMZ+IRN in preclinical neuroblastoma models. The MGMT inhibitor O6BG enhances the anticancer effect of TMZ+IRN in vitro and in vivo.
Article
Oncology
Motoo Nagane, Koichi Ichimura, Ritsuko Onuki, Daichi Narushima, Mai Honda-Kitahara, Kaishi Satomi, Arata Tomiyama, Yasuhito Arai, Tatsuhiro Shibata, Yoshitaka Narita, Takeo Uzuka, Hideo Nakamura, Mitsutoshi Nakada, Yoshiki Arakawa, Takanori Ohnishi, Akitake Mukasa, Shota Tanaka, Toshihiko Wakabayashi, Tomokazu Aoki, Shigeki Aoki, Soichiro Shibui, Masao Matsutani, Keisuke Ishizawa, Hideaki Yokoo, Hiroyoshi Suzuki, Satoshi Morita, Mamoru Kato, Ryo Nishikawa
Summary: This study evaluated the efficacy and safety of bevacizumab in Japanese patients with newly diagnosed glioblastoma and identified an expression classifier that may predict patient prognosis.
Article
Oncology
Henry S. Friedman, Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, W. K. Alfred Yung, Nina Paleologos, Martin K. Nicholas, Randy Jensen, James Vredenburgh, Jane Huang, Maoxia Zheng, Timothy Cloughesy
Summary: This study evaluated the efficacy of bevacizumab, alone or in combination with irinotecan, in recurrent glioblastoma patients. The results showed that bevacizumab, either alone or in combination, was well tolerated and active in treating recurrent glioblastoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Loig Vaugier, Loic Ah-Thiane, Maud Aumont, Emmanuel Jouglar, Mario Campone, Camille Colliard, Ludovic Doucet, Jean-Sebastien Frenel, Carole Gourmelon, Marie Robert, Stephane-Andre Martin, Tanguy Riem, Vincent Roualdes, Loic Campion, Augustin Mervoyer
Summary: The study reviewed elderly patients with GBM referred for 6-week CRT, finding that CRT treatment was feasible for this population, even in the case of post-operative neurological disabilities. Age and neurological disabilities did not necessarily affect patient outcomes.
SCIENTIFIC REPORTS
(2021)
Article
Neurosciences
Xi Chen, Jinli Sun, Yukui Li, Weichao Jiang, Zhangyu Li, Jianyao Mao, Liwei Zhou, Sifang Chen, Guowei Tan
Summary: This study combines metabolomics and proteomics to investigate the methylation mechanism in glioblastoma and identifies prognostic biomarkers for two different types of GBM.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Article
Biochemistry & Molecular Biology
Shao-Wei Feng, Pei-Chi Chang, Hsuan-Yu Chen, Dueng-Yuan Hueng, Yao-Feng Li, Shih-Ming Huang
Summary: Metformin has been shown to effectively reduce cell proliferation and migration, promote cell apoptosis, and disrupt mitochondrial metabolism in glioblastoma cells. Additionally, the combination treatment of metformin and temozolomide has different effects on glioblastoma cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
Katja Werlenius, Sara Kinhult, Tora Skeidsvoll Solheim, Henriette Magelssen, David Loefgren, Munila Mudaisi, Sofia Hylin, Jiri Bartek, Michael Strandeus, Magnus Lindskog, Havyan Bahroz Rashid, Louise Carstam, Sasha Gulati, Ole Solheim, Jiri Bartek, Oyvind Salvesen, Asgeir Store Jakola
Summary: In patients with recurrent glioblastoma, the addition of disulfiram and copper to chemotherapy resulted in significantly increased toxic effects, but no significant difference in survival, according to this multicenter, open-label, randomized phase II/III clinical trial. These findings suggest that disulfiram and copper is without benefit in patients with recurrent glioblastoma.
Article
Oncology
Johannes Weller, Thomas Zeyen, Niklas Schaefer, Christina Schaub, Anna-Laura Potthoff, Joachim P. Steinbach, Peter Hau, Clemens Seidel, Roland Goldbrunner, Ghazaleh Tabatabai, Hartmut Vatter, Theophilos Tzaridis, Matthias Schneider, Ulrich Herrlinger
Summary: The study aimed to replicate the findings of the AVAglio trial regarding the survival benefit of first-line bevacizumab treatment for glioblastoma patients. However, the results of the GLARIUS trial showed that gene expression subgroups were not associated with a differential OS benefit from bevacizumab.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Oncology
K. Ina Ly, Leland G. Richardson, Mofei Liu, Alona Muzikansky, Jonathan Cardona, Kevin Lou, Andrew L. Beers, Ken Chang, James M. Brown, Xiaoyue Ma, David A. Reardon, Isabel C. Arrillaga-Romany, Deborah A. Forst, Justin T. Jordan, Eudocia Q. Lee, Jorg Dietrich, Lakshmi Nayak, Patrick Y. Wen, Ugonma Chukwueke, Anita Giobbie-Hurder, Bryan D. Choi, Tracy T. Batchelor, Jayashree Kalpathy-Cramer, William T. Curry, Elizabeth R. Gerstner
Summary: The efficacy of Bavituximab, a monoclonal antibody with anti-angiogenic and immunomodulatory properties, was evaluated in newly diagnosed patients with glioblastoma (GBM) who also received radiotherapy and temozolomide. The study showed that Bavituximab has activity in the treatment of newly diagnosed GBM and resulted in on-target depletion of intratumoral immunosuppressive MDSCs. Elevated pre-treatment expression of myeloid-related transcripts in GBM may predict response to Bavituximab.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Emilie Le Rhun, Felix Boakye Oppong, Maureen Vanlancker, Roger Stupp, Burt Nabors, Olivier Chinot, Wolfgang Wick, Matthias Preusser, Thierry Gorlia, Michael Weller
Summary: Myelosuppression during temozolomide chemoradiotherapy is associated with the survival of patients with newly diagnosed glioblastoma. Female patients experience more marrow toxicity than males. Lymphopenia is related to the overall survival of patients.
Review
Oncology
P. Trillo Aliaga, F. Spada, G. Peveri, V. Bagnardi, C. Fumagalli, A. Laffi, M. Rubino, L. Gervaso, E. Guerini Rocco, E. Pisa, G. Curigliano, N. Fazio
Summary: The meta-analysis suggested that MGMT status may predict the efficacy of TEM in NETs patients. Patients with MGMT deficiency showed better response rate, progression free survival, and overall survival compared to those with MGMT proficiency.
CANCER TREATMENT REVIEWS
(2021)
Article
Biotechnology & Applied Microbiology
R. J. A. Vibhavari, Vanishree Rao, Sri Pragnya Cheruku, B. Harish Kumar, Swastika Maity, Krishnadas Nandakumar, Lalit Kumar, Chetan Hasmukh Mehta, Usha Nayak, Mallikarjuna Rao Chamallamudi, Nitesh Kumar
Summary: The aim of this study was to investigate the potential of phytochemicals, including rutin, catechin, dehydrozingerone, naringenin, and quercetin, either alone or in combination with temozolomide, to inhibit the expression of MGMT in glioma cells. The results showed that the combination of quercetin and temozolomide effectively reduced temozolomide resistance and could serve as a potential therapeutic target for glioblastoma treatment.
Article
Oncology
Jie Chen, Tingting Wang, Wanming Liu, Hui Qiu, Nie Zhang, Xueting Chen, Xin Ding, Longzhen Zhang
Summary: This study suggests that extended adjuvant temozolomide treatment can significantly improve the prognosis of newly diagnosed glioblastoma patients, regardless of p53 mutation status. The effect of this treatment also varies among patients with different MGMT methylation, IDH1 mutation, and Ki67 expression levels.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Gilbert Youssef, Rifaquat Rahman, Camden Bay, Wei Wang, Mary Jane Lim-Fat, Omar Arnaout, Wenya Linda Bi, Daniel N. Cagney, Yuh-Shin Chang, Timothy F. Cloughesy, Matthew DeSalvo, Benjamin M. Ellingson, Thomas F. Flood, Elizabeth R. Gerstner, L. Nicolas Gonzalez Castro, Jeffrey P. Guenette, Albert E. Kim, Eudocia Q. Lee, Jose R. McFaline-Figueroa, Christopher A. Potter, David A. Reardon, Raymond Y. Huang, Patrick Y. Wen
Summary: This study compared the performance of RANO criteria with modified RANO (mRANO) and immunotherapy RANO (iRANO) criteria in patients with newly diagnosed glioblastoma and recurrent GBM. The results showed similar correlations between PFS and OS for RANO and mRANO. Confirmation scans within 12 weeks after radiotherapy improved correlations in nGBM. Using postradiation MRI as the baseline scan had better correlation in nGBM compared to using pre-radiation MRI. Evaluation of FLAIR sequences did not improve the correlation. iRANO criteria did not provide significant benefit in patients receiving immune checkpoint inhibitors.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Levin Haeni, Monika Kopcic, Mattia Branca, Alessa Schuetz, Michael Murek, Nicole Soell, Erik Vassella, Andreas Raabe, Ekkehard Hewer, Philippe Schucht
Summary: The methylation status of the MGMT gene is a prognostic marker in glioblastoma patients, with >= 16% methylation predicting better survival.
Article
Clinical Neurology
Julia Steinmann, Marion Rapp, Hosai Sadat, Franziska Staub-Bartelt, Bernd Turowski, Hans-Jakob Steiger, Daniel Hanggi, Michael Sabel, Marcel A. Kamp
Summary: This study analyzed the potential relationship between MRI-based apparent diffusion coefficients (ADC) and local recurrence and outcome in patients with brain metastases. The results showed that ADC values did not have a significant impact on local in-brain progression and survival parameters.
BRITISH JOURNAL OF NEUROSURGERY
(2023)
Article
Medicine, Research & Experimental
Christoph Trautwein, Laimdota Zizmare, Irina Maurer, Benjamin Bender, Bjorn Bayer, Ulrike Ernemann, Marcos Tatagiba, Stefan J. Grau, Bernd J. Pichler, Marco Skardelly, Ghazaleh Tabatabai
Summary: This study presents a valuable resource for analyzing tissue metabolites in diffuse glioma patients, revealing the modulations of metabolites by IDH1 mutation, histology, and tumor treatments. Furthermore, tissue metabolites were found to correlate with patient survival, potentially serving as prognostic and surrogate biomarkers in future clinical studies.
Article
Radiology, Nuclear Medicine & Medical Imaging
Jurij Rosen, Garry Ceccon, Elena K. Bauer, Jan-Michael Werner, Caroline Tscherpel, Veronika Dunkl, Marion Rapp, Michael Sabel, Ulrich Herrlinger, Alexander Heinzel, Niklas Schaefer, Maximilian Ruge, Roland Goldbrunner, Gabriele Stoffels, Christoph Kabbasch, Gereon R. Fink, Karl-Josef Langen, Norbert Galldiks
Summary: This study compared the effectiveness and cost effectiveness of F-18-FET PET with conventional MRI for identifying early responders to adjuvant temozolomide chemotherapy. The results showed that F-18-FET PET had a higher rate of correctly identifying responders and was cost-effective compared to MRI.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Clinical Neurology
Pia S. Zeiner, Katharina Filipski, Natalie Filmann, Marie-Therese Forster, Martin Voss, Emmanouil Fokas, Ulrich Herrlinger, Patrick N. Harter, Joachim P. Steinbach, Michael W. Ronellenfitsch
Summary: This study retrospectively analyzed 492 patients with glioma undergoing temozolomide-based concomitant radiochemotherapy and found that women were more prone to severe cytopenia. Severe myelosuppression correlated with worse overall survival (OS) in women.
Article
Oncology
Johannes Weller, Niklas Schaefer, Christina Schaub, Anna-Laura Potthoff, Joachim P. Steinbach, Uwe Schlegel, Michael Sabel, Peter Hau, Clemens Seidel, Dietmar Krex, Roland Goldbrunner, Torsten Pietsch, Theophilos Tzaridis, Thomas Zeyen, Valeri Borger, Erdem Guresir, Hartmut Vatter, Ulrich Herrlinger, Matthias Schneider
Summary: Obesity is associated with shorter survival in patients with MGMT methylated glioblastoma, but not in patients with MGMT unmethylated glioblastoma.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Oncology
Anna-Luisa Luger, Sven Koenig, Patrick Felix Samp, Hans Urban, Iris Dive, Michael C. Burger, Martin Voss, Kea Franz, Emmanouil Fokas, Katharina Filipski, Melanie-Christin Demes, Albrecht Stenzinger, Felix Sahm, David E. Reuss, Patrick N. Harter, Sebastian Wagner, Elke Hattingen, Jennifer Wichert, Constantin Lapa, Stefan Froehling, Joachim P. Steinbach, Michael W. Ronellenfitsch
Summary: This study aimed to evaluate the decision-making process and efficacy of molecular targeted therapies in brain tumor patients. They found that molecular matched targeted therapies showed efficacy in some tumor types, especially those with oncogenic drivers like BRAF mutations. However, further research is needed for rare tumor types such as medulloblastoma and papillary craniopharyngeoma.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Clinical Neurology
Nora F. Dengler, Christoph Scholz, Juergen Beck, Anne-Kathrin Uerschels, Ullrich Sure, Christian Scheller, Christian Strauss, Daniel Martin, Gabriele Schackert, Christian Heinen, Johannes Woitzik, Anna Lawson McLean, Steffen K. Rosahl, Jonas Kolbenschlag, Johannes Heinzel, Martin Schuhmann, Marco Soares Tatagiba, Waltraud Kleist-Welch Guerra, Henry W. S. Schroeder, Ignazio Gaspare Vetrano, Rezvan Ahmadi, Andreas Unterberg, Jennifer Reinsch, Anna Zdunczyk, Meike Unteroberdoerster, Peter Vajkoczy, Sarah Wehner, Michael Becker, Cordula Matthies, Jose Perez-Tejon, Annie Dubuisson, Damiano G. Barrone, Rikin Trivedi, Crescenzo Capone, Stefano Ferraresi, Jakob Kraschl, Thomas Kretschmer, Thomas Dombert, Frank Staub, Michael Ronellenfitsch, Gerhard Marquardt, Vincent Prinz, Marcus Czabanka, Anne Carolus, Veit Braun, Ralph Koenig, Gregor Antoniadis, Christian Rainer Wirtz, Lukas Rasulic, Maria Teresa Pedro
Summary: This is a registry study on peripheral nerve tumors (PNT) aiming to systematically investigate the epidemiology, clinical symptoms, treatment strategies and outcomes, genetic and histopathologic features, as well as imaging characteristics of PNT. The study aims to improve understanding of PNT and assist future interventional studies.
NEUROLOGICAL RESEARCH
(2023)
Article
Oncology
Tareq M. Haedenkamp, Michael F. Leitzmann, Ralf A. Linker, Christoph Meier, Claudia Becker, Susan Jick, Peter Hau, Corinna Seliger
Summary: This large case-control study investigated the association between antibiotic use and the risk of glioma. The results showed no significant increase in glioma risk after antibiotic use, and the use of polyenes may be weakly associated with a decreased risk of glioma.
Article
Cell Biology
Iris Dive, Kevin Klann, Jonas B. Michaelis, Dennis Heinzen, Joachim P. Steinbach, Christian Muench, Michael W. Ronellenfitsch
Summary: Under conditions of hypoxia and starvation, autophagy is strongly induced and further enhanced by mTOR inhibition in glioma cells. While the mTOR inhibitor torin2 enhances glioma cell survival, co-treatment with torin2 and the autophagy inhibitor bafilomycin A1 fails to promote cell death. Treatment with bafilomycin A1 alone also protects glioma cells from cell death.
CELL DEATH DISCOVERY
(2022)
Article
Oncology
J. Weller, N. Schaefer, C. Schaub, T. Tzaridis, T. Zeyen, M. Schneider, A. L. Potthoff, F. A. Giordano, J. P. Steinbach, P. S. Zeiner, T. Kowalski, M. Sabel, P. Hau, D. Krex, O. Grauer, R. Goldbrunner, O. Schnell, G. Tabatabai, F. Ringel, F. Schmidt-Graf, S. Brehmer, J. C. Tonn, L. Bullinger, P. Vajkoczy, M. Glas, H. Vatter, U. Herrlinger, C. Seidel
Summary: In the CeTeG/NOA-09 randomized phase III trial, TMZ/CCNU combination therapy was found to be superior to TMZ in newly diagnosed MGMT methylated glioblastoma, with higher incidence of hematotoxicity. This study analyzed high-grade hematotoxicity and its prognostic relevance in the trial population.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Corinna Seliger, Lisa Rauer, Anne-Louise Wuester, Sylvia Moeckel, Verena Leidgens, Birgit Jachnik, Laura-Marie Ammer, Simon Heckscher, Katja Dettmer, Markus J. Riemenschneider, Peter J. Oefner, Martin Proescholdt, Arabel Vollmann-Zwerenz, Peter Hau
Summary: Metformin has inhibitory effects on brain tumor-initiating cells (BTICs), but its effectiveness in vivo remains unclear. It was found that BTICs of different molecular subtypes have distinct amino acid profiles, and metformin treatment can inhibit their growth in vitro.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Clinical Neurology
Michal Ziga, Marketa Sosnova, Anna M. Zeitlberger, Luca Regli, Oliver Bozinov, Astrid Weyerbrock, John K. Ratliff, Martin N. Stienen, Nicolai Maldaner
Summary: This study aimed to investigate the application of a smartphone-based 6-minute walking test in patients with degenerative lumbar disorders after surgery. The study found that this test could objectively assess patients' functional impairment and detect changes in their recovery after surgery. Additionally, a ceiling effect was observed in some patients, indicating that their patient-reported outcome measures could not further improve.
Article
Oncology
Johannes Weller, Thomas Zeyen, Niklas Schaefer, Christina Schaub, Anna-Laura Potthoff, Joachim P. Steinbach, Peter Hau, Clemens Seidel, Roland Goldbrunner, Ghazaleh Tabatabai, Hartmut Vatter, Theophilos Tzaridis, Matthias Schneider, Ulrich Herrlinger
Summary: The study aimed to replicate the findings of the AVAglio trial regarding the survival benefit of first-line bevacizumab treatment for glioblastoma patients. However, the results of the GLARIUS trial showed that gene expression subgroups were not associated with a differential OS benefit from bevacizumab.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Oncology
Franziska Staub-Bartelt, Julia Steinmann, Oliver Radtke, Daniel Haenggi, Michael Sabel, Marion Rapp
Summary: The COVID-19 pandemic does not significantly affect the prevalence of distress, anxiety, and depression in neuro-oncological patients. There is no significant difference in the rates of these psychological issues compared to before the pandemic.
Article
Clinical Neurology
Leonore Purwien, Susanne Schubert-Bast, Matthias Kieslich, Michael W. Ronellenfitsch, Michael Merker, Marcus Czabanka, Laurent M. Willems, Felix Rosenow, Adam Strzelczyk
Summary: Midazolam has become the preferred benzodiazepine for both children and adults in pre- and in-hospital settings, with newer ASMs such as levetiracetam and lacosamide showing increased usage over time while older ASMs like phenobarbital, phenytoin, and valproate have decreased. Despite changes in medication patterns, mortality and outcomes have remained stable.